Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05559008
Other study ID # PTCL-IIT-umbrella
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 30, 2022
Est. completion date January 26, 2026

Study information

Verified date November 2022
Source Ruijin Hospital
Contact Weili Zhao
Phone +862164370045
Email zwl_trial@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell lymphoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 116
Est. completion date January 26, 2026
Est. primary completion date March 26, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically-confirmed Peripheral T-cell lymphoma (without central nervous system involvement) 2. Relapsed or refractory disease after first line treatment 3. Availability of archival or freshly collected tumor tissue before study enrollment 4. Evaluable lesion by PET-CT or CT scan 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 6. Life expectancy greater than or equal to (>/=) 3 months 7. Informed consent Exclusion Criteria: 1. Patients with central nervous system (CNS) lymphoma 2. History of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix 3. Uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases 4. Laboratory measures meet the following criteria at screening (unless caused by lymphoma): Neutrophils<1.0×10^9/L Platelets<75×10^9/L (Platelets<50×10^9/L in case of bone marrow involvement) ALT or AST is 2.5 times higher than the upper limits of normal (ULN), AKP and bilirubin are 1.5 times higher than the ULN. Creatinine is 1.5 times higher than the ULN. 5. HIV-infected patients 6. Active hepatitis infection 7. Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol 8. Pregnant or lactation 9. Other medical conditions determined by the researchers that may affect the study For T3.2 should exclude patiens with active autoimmune disease

Study Design


Intervention

Drug:
Azacitidine Injection
Azacitidine Injection,SC and Dasatinib PO will be administered in T1 subtypes
Dasatinib
Azacitidine Injection,SC and Dasatinib PO will be administered in T1 subtypes
Linperlisib
Azacitidine Injection,SC and Linperlisib PO will be administered in T2 subtypes
Tucidinostat
Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
SHR2554
Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Camrelizumab
Camrelizumab and Apatinib will be administered in T3.2 subtypes
Apatinib
Camrelizumab and Apatinib will be administered in T3.2 subtypes

Locations

Country Name City State
China Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate Percentage of participants with complete and partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria. End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6)(each cycle is 28 days)
Secondary Complete response rate Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria. End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6)(each cycle is 28 days)
Secondary Progression-free survival Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first. Baseline up to data cut-off (up to approximately 2 years)
Secondary Overall survival Overall survival was defined as the time from the date of enrollment to the date of death from any cause. Baseline up to data cut-off (up to approximately 2 years)
Secondary Duration of response Duration of response was defined as the time from the date of favorable response until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria Baseline up to data cut-off (up to approximately 2 years)
Secondary Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. From enrollment to study completion, a maximum of 4 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT06083701 - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Phase 1/Phase 2
Not yet recruiting NCT02856997 - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04083495 - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Phase 2
Not yet recruiting NCT05979792 - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma Early Phase 1
Recruiting NCT04984837 - Study of Lacutamab in Peripheral T-cell Lymphoma Phase 2
Recruiting NCT06072131 - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Phase 3
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Terminated NCT03947255 - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04028440 - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Early Phase 1
Not yet recruiting NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting NCT05883449 - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Phase 2
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Active, not recruiting NCT03586999 - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Phase 1/Phase 2
Recruiting NCT04489264 - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting NCT06151106 - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Phase 2
Recruiting NCT02753543 - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Phase 2
Not yet recruiting NCT06089941 - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution